Latest Breaking News On - Graft versus host disease - Page 9 : vimarsana.com

Alternative Antirejection Regimen in Pediatric Heart Transplant

Results of the head-to-head TEAMMATE trial show the combination of everolimus and low-dose tacrolimus can be considered an alternative to MMF plus tacrolimus in pediatric heart transplant.

Salt lake cityUnited statesUniversity of utahJoseph rossanoAntoniog cabreraChristopher almondHeart failureTransplantation pediatricTransplantation heartCardiac transplantationRansplantation cardiacHeart transplantationGraft versus host diseaseCalcineurin inhibitorMtor inhibitorAmmalian target of rapamycin inhibitor

Live Biotherapeutic Product (LBP) Market worth $ 2 60 billion by 2030 - Exclusive Report by InsightAce Analytic

Live Biotherapeutic Product (LBP) Market worth $ 2 60 billion by 2030 - Exclusive Report by InsightAce Analytic
newyorktelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newyorktelegraph.com Daily Mail and Mail on Sunday newspapers.

New zealandSouth koreaSwitzerland generalCh ungch ong namdoSouth africaUnited statesAsia pacificExegi pharmaDermbiont incSeres therapeutics incOptibiotix health plcPuretech health plcSee campaignTakeda pharmaceutical coMybiotics pharmaBiomica ltd

FDA Grants Orphan Designation for Lipella s LP-310 Drug Candidate for Oral Graft-versus-Host Disease

/PRNewswire/ Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical stage pharmaceutical company addressing serious diseases with significant unmet need.

United statesJeff ramsonJonathan kaufmanLipella pharmaceuticalsLipella pharmaceuticals incDrug administrationLipella pharmaceuticalGraft versus host diseaseChief executive officerOrphan drug designationMichael chancellorChief medical officerVersus host diseaseLipella pharmaceuticals inc

Lipella Pharmaceuticals (LIPO) Granted FDA Orphan Designation for LP-310

Lipella Pharmaceuticals (LIPO) Granted FDA Orphan Designation for LP-310
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJonathan kaufmanLipella pharmaceuticals incDrug administrationLipella pharmaceuticalsGraft versus host diseaseChief executive officerOrphan drug designationChief medical officer

MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results

MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesCity ofUnited kingdomSan franciscoLou gehrigEarly access program of maaSenior pr corporate communicationsCompany early access program of maaCellulaire congressTrophic communicationsEuropean medicines agencyMicrobiome therapeutics innovation groupSociety for immunotherapy of cancerAmerican society of hematologyIndependent data safety monitoring board